Deerfield Imaging announces acquisition of IMRIS

Deerfield Imaging announced last week that it has completed its acquisition of “certain assets and liabilities” of IMRIS, a company that specializes in image-guided therapy and had filed for bankruptcy.

Deerfield Imaging is a wholly owned business of Deerfield Management Company, a healthcare investment firm that had been working with IMRIS since 2013.

Jay D. Miller, Deerfield Imaging President and CEO, said his company is excited that the deal is now finalized, and that IMRIS has a great reputation within the industry.

“Top neuroscience centers equate the IMRIS brand with turnkey design services, program management, and clinical training that delivers smooth integration of imaging in the operating room,” Miller said in a statement. “Deerfield Imaging will continue developing new products under the IMRIS brand and invest in clinical studies to demonstrate the clinical and economic value of IMRIS surgical solutions.”

Teb Huber, a partner at Deerfield Management, also commented on the deal, praising the legacy of IMRIS’ VISIUS Surgical Theatre.

“IMRIS is enhancing the quality of neurosurgical procedures and improving patient outcomes,” he said. “Nearly 20,000 patients have benefitted from procedures in VISIUS Surgical Theatres and we look forward to seeing that number continue to grow.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.

And it can do so with almost 100% accuracy as a first reader, according to a new large-scale analysis.

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.